The Oral Typhoid Vaccine Market is expanding as governments and healthcare organizations increase efforts to prevent typhoid fever through vaccination. The market was valued at USD 900 million in 2025 and is projected to reach USD 2 billion by 2035, growing at a CAGR of 7.8% during 2026–2035.
Vaccine development is focusing on improved oral formulations, better stability, and easier administration. Single-dose oral approaches are gaining attention because they can simplify vaccination programs, while advances in formulation and delivery are helping improve accessibility in areas with limited healthcare infrastructure.
The market includes live attenuated, inactivated, and conjugate vaccine products for children, adults, and elderly populations. Public health programs represent an important area of use, while private clinics and pharmaceutical distributors also support vaccine access through different healthcare channels.
Asia-Pacific is expected to lead the market because of the higher prevalence of typhoid and expanding immunization initiatives. North America and Europe maintain established vaccination systems, while South America and the Middle East and Africa are gradually developing through improved healthcare infrastructure and public-health programs.
Future opportunities include combination vaccines, improved oral delivery technologies, temperature-stable formulations, and stronger vaccination programs in underserved regions. Better disease surveillance and collaboration between governments, healthcare organizations, and vaccine manufacturers could further support market expansion.
